RenaMed Biologics has presented positive preliminary results from its Phase II trial of its renal bio-replacement therapy to treat patients with acute renal failure, or acute kidney injury. The study of 58 patients found that RenaMed's therapy increased survival rate by 72 percent at 28 days, a trend for improved survival sustained through 90 and 180 days. The preliminary results were presented at the 38th annual meeting of the American Society of Nephrology in Philadelphia, Pa.
While dialysis and hemofiltration replace the waste and fluid balance functions of the kidney, these processes do not replace the kidney's essential metabolic and endocrine functions. Bio-replacement therapy is designed to replace these additional, essential kidney functions during a critical phase of acute renal failure and to work in conjunction with existing hemofiltration systems to provide comprehensive kidney function support.